AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28320361 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza
Number of subjects: 500000
Study 28320361 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV
Number of subjects: 500000
Study 28320361 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk status
Number of subjects: 500000
Study 28320361 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza B
Number of subjects: 500000
Study 28320361 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV hospitalizations
Number of subjects: 500000
Study 28320486 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hepatectomy with the left jackknife position
Number of subjects: 10
Study 28320707 — intervention group
Group type: COMPARATOR
Intervention: Procedures in lower volume centers (200-399 PCI cases per year)
Number of subjects: 427467
Study 28320707 — intervention group
Group type: COMPARATOR
Intervention: Procedures in higher volume centers (1500-1999 PCI cases per year)
Number of subjects: 427467
Study 28320707 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 427467
Study 28320707 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PCI cohort
Number of subjects: 427467
Study 28320791 — intervention group
Group type: COMPARATOR
Intervention: No to mild PLE
Number of subjects: 62
Study 28320791 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe PLE
Number of subjects: 62
Study 28320791 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of PLE (follow-up)
Number of subjects: 62
Study 28320791 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA-class (follow-up)
Number of subjects: 62
Study 28320796 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazardous alcohol consumption (Alcohol Use Disorders Identification Test-C score ≥3)
Number of subjects: 571
Study 28320796 — intervention group
Group type: COMPARATOR
Intervention: Low alcohol intake
Number of subjects: 571
Study 28320796 — intervention group
Group type: COMPARATOR
Intervention: Depressive symptoms, non-specific psychological distress, physical and psychological IPV
Number of subjects: 571
Study 28320796 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 571
Study 28321002 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral approach (TF)
Number of subjects: 64
Study 28321002 — intervention group
Group type: EXPERIMENTAL
Intervention: Transapical approach (TA)
Number of subjects: 64
Study 28321002 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild or greater aortic regurgitation (AR) at 1 week
Number of subjects: 64
Study 28321002 — intervention group
Group type: EXPERIMENTAL
Intervention: High STS score (>8)
Number of subjects: 64
Study 28321003 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI with the CoreValve System (26-mm/29-mm cohort)
Number of subjects: 75
Study 28321003 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI with the CoreValve System (23-mm cohort)
Number of subjects: 75
Study 28321004 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip
Number of subjects: 30
Study 28322082 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation PET radioligands for TSPO
Number of subjects: 0
Study 28322082 — intervention group
Group type: COMPARATOR
Intervention: Prototypical PET radioligand for TSPO
Number of subjects: 0
Study 28322812 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 28323236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored ventilator regimens based on lung morphology
Number of subjects: 0
Study 28323236 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation with low tidal-volumes (Vt) targeting a plateau pressure ≤30 cmH2O
Number of subjects: 0
Study 28323923 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variation affecting FSH production (FSHB c.-211G>T)
Number of subjects: 1554
Study 28323923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligand-receptor variant combination resulting in weak FSH action
Number of subjects: 1554
Study 28323923 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI z score
Number of subjects: 1554
Study 28323951 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubly labeled water (DLW) study
Number of subjects: 28
Study 28323951 — intervention group
Group type: COMPARATOR
Intervention: Common prediction equations for TDEE
Number of subjects: 28
Study 28323951 — intervention group
Group type: COMPARATOR
Intervention: Hyperinsulinemia
Number of subjects: 28
Study 28323951 — intervention group
Group type: COMPARATOR
Intervention: Hyperandrogenemia
Number of subjects: 28
Study 28323951 — intervention group
Group type: EXPERIMENTAL
Intervention: Equation derived from DLW
Number of subjects: 28
Study 28323960 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact FGF23
Number of subjects: 90
Study 28323960 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum phosphate and renal phosphate excretion
Number of subjects: 90
Study 28323960 — intervention group
Group type: EXPERIMENTAL
Intervention: C-terminal FGF23
Number of subjects: 90
Study 28323970 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocyte gene expression in OW women
Number of subjects: 24
Study 28323970 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum and FF hormone and lipid levels in OW women
Number of subjects: 24
Study 28323970 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition metrics in OW women
Number of subjects: 24
Study 28323999 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically healthy obese men
Number of subjects: 6238
Study 28323999 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically healthy obese women
Number of subjects: 6238
Study 28323999 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically healthy overweight men
Number of subjects: 6238
Study 28323999 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically healthy overweight women
Number of subjects: 6238
Study 28324009 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES)
Number of subjects: 27
Study 28324009 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated WES data
Number of subjects: 27
Study 28324018 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest TSH tertile (2.14 to 86.7 mIU/L)
Number of subjects: 541
Study 28324018 — intervention group
Group type: COMPARATOR
Intervention: Lowest TSH tertile (<1.28 mIU/L)
Number of subjects: 541
Study 28324042 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (anakinra/Kineret®, total dose 3 × 100 mg)
Number of subjects: 73
Study 28324110 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (0.04 to 0.19 mg/kg/d)
Number of subjects: 53
Study 28324749 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR405838 400 mg QD
Number of subjects: 74
Study 28324749 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR405838 300 mg QD
Number of subjects: 74
Study 28324749 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR405838 weekly schedule
Number of subjects: 74
Study 28324749 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR405838 1800 mg twice weekly
Number of subjects: 74
Study 28324749 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR405838
Number of subjects: 74
Study 28324749 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR405838 in de-differentiated liposarcoma MTD cohort
Number of subjects: 74
Study 28324891 — intervention group
Group type: EXPERIMENTAL
Intervention: MSKCC nomogram and Tenon score (low risk: ⩽10% probability of metastatic non-SN and Tenon score ⩽3.5)
Number of subjects: 2822
Study 28324891 — intervention group
Group type: COMPARATOR
Intervention: High risk group (not specified intervention)
Number of subjects: 2822
Study 28325399 — intervention group
Group type: EXPERIMENTAL
Intervention: Hedgehog pathway inhibitor therapy
Number of subjects: 0
Study 28325769 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraminidase antibody responses measured by ELISA
Number of subjects: 0
Study 28325769 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraminidase inhibition assays
Number of subjects: 0
Study 28325769 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies binding to the conserved stalk domain of hemagglutinin
Number of subjects: 0
Study 28325785 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (specific details not available)
Number of subjects: 0
Study 28325783 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter 2 inhibition (chronic, 4 weeks)
Number of subjects: 66
Study 28325857 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment, cryotherapy, vascular endothelial growth factor (VEGF) inhibitor, vitrectomy/scleral buckling, or a combination thereof.
Number of subjects: 327
Study 28326189 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg + csDMARDs
Number of subjects: 546
Study 28326189 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg + csDMARDs
Number of subjects: 546
Study 28326189 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab + csDMARDs
Number of subjects: 546
Study 28326189 — intervention group
Group type: COMPARATOR
Intervention: Placebo + csDMARDs
Number of subjects: 546
Study 28326509 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoassays (IAs)
Number of subjects: 27
Study 28326509 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-chromatography tandem mass-spectrometry (LC-MS/MS)
Number of subjects: 27
Study 28326509 — intervention group
Group type: COMPARATOR
Intervention: Both IAs and LC-MS/MS after hCG stimulation
Number of subjects: 27
Study 28326839 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat
Number of subjects: 0
Study 28326839 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane + Entinostat
Number of subjects: 0
Study 28326839 — intervention group
Group type: COMPARATOR
Intervention: Exemestane + Placebo
Number of subjects: 0
Study 28326849 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with recombinant factor VIII (rFVIII)
Number of subjects: 183
Study 28327100 — intervention group
Group type: EXPERIMENTAL
Intervention: CME-M (Continuing Medical Education meeting)
Number of subjects: 396
Study 28327100 — intervention group
Group type: COMPARATOR
Intervention: Non-participating reference practices
Number of subjects: 396
Study 28327104 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional principal component analysis (FPCA) for modeling height-for-age z-scores (HAZ) over the first 24 months of life.
Number of subjects: 626
Study 28327104 — intervention group
Group type: EXPERIMENTAL
Intervention: Adj-FPC2 score derived from FPCA.
Number of subjects: 626
Study 28327104 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors associated with growth faltering identified through linear regression.
Number of subjects: 626
Study 28327200 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2787106 (0.3-10 mg/kg every 3 weeks)
Number of subjects: 33
Study 28327200 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2787106 (10 mg/kg weekly)
Number of subjects: 33
Study 28327462 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected subjects on cART
Number of subjects: 45
Study 28327462 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 45
Study 28327905 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib 150 mg two times daily (increased to 300 mg two times daily at disease progression)
Number of subjects: 25
Study 28327905 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib
Number of subjects: 25
Study 28327908 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted plasma 25(OH)D score (highest quintile)
Number of subjects: 1016
Study 28327953 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line everolimus followed by second-line sunitinib
Number of subjects: 471
Study 28327953 — intervention group
Group type: COMPARATOR
Intervention: First-line sunitinib followed by second-line everolimus
Number of subjects: 471
Study 28327958 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem-cell transplantation (ASCT)
Number of subjects: 1045
Study 28327958 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation in an independent sample of 389 patients
Number of subjects: 1045
Study 28327988 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 42
Study 28327988 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC)
Number of subjects: 42
Study 28328966 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of family planning (FP) services into HIV care clinics at six delayed integration clinics.
Number of subjects: 5682
Study 28328966 — intervention group
Group type: EXPERIMENTAL
Intervention: Early integration of FP and HIV services at twelve early integration sites.
Number of subjects: 5682
Study 28328966 — intervention group
Group type: COMPARATOR
Intervention: All 18 integrated sites in year two.
Number of subjects: 5682
Study 28329053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 17
Study 28329053 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study 28329198 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) implantation
Number of subjects: 101
Study 28329286 — intervention group
Group type: EXPERIMENTAL
Intervention: MGN1703 (60 mg subcutaneously twice weekly for 4 weeks)
Number of subjects: 15
Study 28329385 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined left atrial volume index (LAVI) >40 ml/m2 and tricuspid regurgitation (TR) >3.1 m/s
Number of subjects: 237
Study 28329393 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line ART based on ritonavir-boosted lopinavir combined with zidovudine or tenofovir plus lamivudine or emtricitabine
Number of subjects: 101
Study 28329393 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculosis treatment
Number of subjects: 101
Study 28330462 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus, administered orally at a daily dose of 10 mg continuously (28-day cycles).
Number of subjects: 10
Study 28330651 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion of IVUS and OCT imaging
Number of subjects: 72
Study 28330651 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT imaging
Number of subjects: 72
Study 28330670 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) for evaluating CAV severity
Number of subjects: 62
Study 28330670 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LFP and bright spots
Number of subjects: 62
Study 28330907 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ω-3 fatty acids
Number of subjects: 0
Study 28331015 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically recorded alcohol consumption
Number of subjects: 0
Study 28331015 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28331539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 5 μg
Number of subjects: 0
Study 28331539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28331611 — intervention group
Group type: EXPERIMENTAL
Intervention: One ultrasound-guided high-intensity focused ultrasound (HIFU) treatment
Number of subjects: 20
Study 28331611 — intervention group
Group type: EXPERIMENTAL
Intervention: Two ultrasound-guided high-intensity focused ultrasound (HIFU) treatments
Number of subjects: 20
Study 28331623 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA) 30 g/day for 12 weeks
Number of subjects: 47
Study 28331623 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA)
Number of subjects: 47
Study 28331988 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing of cardiac autonomic function by means of short-term deceleration capacity (DC) of heart rate
Number of subjects: 1821
Study 28332144 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira in DUAL I (n=1663) vs. insulin degludec or liraglutide 1.8 mg; 52 weeks
Number of subjects: 379
Study 28332144 — intervention group
Group type: COMPARATOR
Intervention: IDegLira in DUAL IV (n=435) vs. placebo; 26 weeks
Number of subjects: 379
Study 28332144 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira in DUAL II (n=398) vs. insulin degludec; 26 weeks
Number of subjects: 379
Study 28333699 — intervention group
Group type: EXPERIMENTAL
Intervention: sf-IL-6
Number of subjects: 104
Study 28333699 — intervention group
Group type: EXPERIMENTAL
Intervention: C1M
Number of subjects: 104
Study 28333704 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma:RBC ratio (≥1 plasma unit:1 RBC unit)
Number of subjects: 324
Study 28333704 — intervention group
Group type: EXPERIMENTAL
Intervention: High PLT:RBC ratio (≥0.2 PLT doses:1 RBC unit)
Number of subjects: 324
Study 28333704 — intervention group
Group type: COMPARATOR
Intervention: Low plasma:RBC ratio
Number of subjects: 324
Study 28333704 — intervention group
Group type: COMPARATOR
Intervention: Low PLT:RBC ratio
Number of subjects: 324
Study 28333976 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hs-TnI) baseline cutoff of 150 ng/L
Number of subjects: 1516
Study 28333976 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hs-TnI) change of 20 ng/L after 1 hour
Number of subjects: 1516
Study 28333976 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hours ESC algorithm
Number of subjects: 1516
Study 28333976 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour ESC algorithm
Number of subjects: 1516
Study 28333976 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional application of an ischemic ECG
Number of subjects: 1516
Study 28334685 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation or exercise
Number of subjects: 225
Study 28334685 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral pathogen detected
Number of subjects: 225
Study 28334685 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza infections
Number of subjects: 225
Study 28334685 — intervention group
Group type: EXPERIMENTAL
Intervention: Early IP-10 concentration measurement
Number of subjects: 225
Study 28335038 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated education intervention (INT)
Number of subjects: 530
Study 28335038 — intervention group
Group type: COMPARATOR
Intervention: CVD-specific education intervention (C)
Number of subjects: 530
Study 28335733 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term hyperoxia (2-hour exposure)
Number of subjects: 20
Study 28335798 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg subcutaneous daily (with escalation to 200 mg and 300 mg)
Number of subjects: 6
Study 28335798 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 200 mg
Number of subjects: 6
Study 28335798 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 300 mg
Number of subjects: 6
Study 28335798 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg
Number of subjects: 6
Study 28335798 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (all doses)
Number of subjects: 6
Study 28335823 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Readiness Consultation Tool (CRCT)
Number of subjects: 53
Study 28335823 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot testing of the CRCT
Number of subjects: 53
Study 28336527 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor (60 mg)
Number of subjects: 95
Study 28336743 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower socioeconomic position (SEP) indicators such as fewer assets and having a daily wage labourer as the highest occupation.
Number of subjects: 165233
Study 28336743 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of education.
Number of subjects: 165233
Study 28336780 — intervention group
Group type: EXPERIMENTAL
Intervention: Tau Tracer
Number of subjects: 0
Study 28336780 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28337155 — intervention group
Group type: EXPERIMENTAL
Intervention: Different e-Cigarette Generation and Models
Number of subjects: 0
Study 28337324 — intervention group
Group type: EXPERIMENTAL
Intervention: GBT440 (dosage and duration not specified)
Number of subjects: 0
Study 28337781 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management (antithrombotic therapy)
Number of subjects: 0
Study 28337781 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional management
Number of subjects: 0
Study 28337781 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 0
Study 28337781 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28338153 — intervention group
Group type: EXPERIMENTAL
Intervention: Different reconstruction methods for total gastrectomy
Number of subjects: 11872
Study 28339149 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor hydrochloride 15 mg twice daily before food
Number of subjects: 18
Study 28339149 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor hydrochloride 15 mg twice daily after food
Number of subjects: 18
Study 28339149 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor hydrochloride 15 mg twice daily while fasting
Number of subjects: 18
Study 28339500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 2933
Study 28339500 — intervention group
Group type: COMPARATOR
Intervention: Placebo prophylaxis
Number of subjects: 2933
Study 28339607 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor trajectories assessment using Alberta Infant Motor Scales at 4, 6, 9, and 12 months
Number of subjects: 342
Study 28339607 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor trajectories predictive of 24-month cognitive and motor outcomes
Number of subjects: 342
Study 28339607 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analyses for influencing factors
Number of subjects: 342
Study 28339818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 240
Study 28339818 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVIAR response score
Number of subjects: 240
Study 28340695 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived stromal vascular fraction injection
Number of subjects: 12
Study 28340695 — intervention group
Group type: COMPARATOR
Intervention: Iloprost infusion (previously received by 8 patients)
Number of subjects: 12